Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Ladenburg Thalmann 2019 Healthcare Conference
22 slides from Armata Pharmaceuticals's conference presentation, Sep 24, 2019
Slide 1: Ladenburg Thalmann 2019 Healthcare Conference
Todd Patrick, Chief Executive Officer Ladenburg Thalmann 2019 Healthcare Conference New York, NY September 24, 2019 NYSE American: ARMP
Slide 2: Forward-looking statements
2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All
Slide 3: Investment Highlights: A World-Leader in Phage Therapeutics
3 I • Phage discovery and synthetic biology yield robust pipeline – Newly improved P. aeruginosa phage product candidate developing rapidly • Cystic fibrosis phage product candidate identified • Synthetic phage with improved pharmacology engineered – S. aureus phage product candidate advanced throug
Slide 4: Armata Stands on Long History of Phage Development
4 I Armata Stands on Long History of Phage Development M&A Yields Leading Phage Company Biocontrol Ltd. Pre - IND S. aureus and P. aeruginosa phage SGI Asset Acquisition Synthetic phage platform ▪ Pseudomonas program ▪ Pharma partnered program GMP Facility 25 MDR Cases Under EIND Targeted Antimicrob
Slide 5: Leadership and Board of Directors
5 I Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Todd R. Patrick CEO Steve Martin CFO Brian Varnum President and CDO Duane Morris VP, Operations Board of Directors Richard Bastiani Chair Joseph M. Patti Richard Bear Michael S. Perry Jeremy Curnock Co
Slide 6: Unmet Need in Antibiotic Resistant Infections
6 I Unmet Need in Antibiotic Resistant Infections Phages May Provide a Powerful Solution to an Urgent Public Health Threat Aug 2019 Xenleta (lefamulin)
Slide 7: Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis
7 I Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis Source: Prescott Harley Klein’s Microbiology, 7th Ed. • The most ubiquitous organisms on Earth • Natural predators of bacteria • Highly targeted • Prior history as therapeutic agent – Antibiotics displaced phage use • Drug -
Slide 8: Deadly Infections Successfully Treated With Phage
8 I Deadly Infections Successfully Treated With Phage Aortic Graft Pseudomonas Cystic Fibrosis Pseudomonas Cystic Fibrosis Pseudomonas Cystic Fibrosis NTM
Slide 9: Phage Therapy Now And In the Future
9 I Phage Therapy Now And In the Future Moving Phage Into Formal Trials and Towards Commercialization Armata’s Vision • Life - changing outcomes in EIND cases – Sufficient proof to advance to formal clinical trials • Highly specific bactericidal agents – Minimal disruption of microbiome • Mechanism
Slide 10: Pipeline
10 I Pipeline Pathogen Discovery Preclinical Clinical Plans / Indications Pseudomonas aeruginosa Staphylococcus aureus Undisclosed Partnered AP - PA02 Phage libraries to address market expansion and new indications AP - SA01 AP - SA02 Respiratory Infections Ph 1 in Cystic Fibrosis Patients in 2020 U
Slide 11: Cystic Fibrosis and Pseudomonas aeruginosa: Respiratory Opportunity
11 I Cystic Fibrosis • High prevalence of PA in all ages • Increased risk of death at 8 years in children with PA infection • Greater deterioration in lung function of PA - infected adolescents • Total antibiotic sales in CF market projected to be >$400M in 2020 • Potential uses as frontline therapy
Slide 12: Robust Integrated Approach Yields Improved Product Form
12 I In Vitro Killing Kinetics In Vivo Screening Manufacturing Feasibility Robust Integrated Approach Yields Improved Product Form AP - PA02 surveillance Candidate Screening Lead phage pool Identify receptors Genomic analysis ID phage family Confirm lytic Broaden Host Range Candidate pool with desir
Slide 13: AP-PA02: Product Development Status
13 I • Robust product profile – Distinct families – Targets 4 different receptor classes – Cooperative/compatible – Broadly active against clinical isolates – Highly potent • Initiated manufacturing of clinical trial material (CTM) • Near - term regulatory filing anticipated • Phase 1 site identifie
Slide 14: AP-PA02: Formulation and Production
14 I AP - PA02: Formulation and Production Utilizing Armata’s Proprietary Phage - Specific GMP Capabilities Liquid formulation selected Feasibility batches completed Verification batches completed Clinical batches underway to support near - term IND Suitable for inhalation and IV All intended specif
Slide 15: AP-PA02: Clinical Outline
15 I Near - term study Follow - on studies Future Opportunities AP - PA02: Clinical Outline Patient population: Medically stable chronically - infected CF patients Route of administration: Nebulized Goals: Safety and tolerability, PK, dose exploration Efficacy endpoints in CF populations Chronically
Slide 16: Armata's Vision: Improvements Through Engineering
16 I Armata’s Vision: Improvements Through Engineering Comparative Genomics 0 20 40 60 80 100 B i o f i l m ( % ) Natural Expanded Host Range Biofilm Disruptor Improved in vitro Biofilm Activity (40 clinical isolates) Single ORF driving host range Engineer super fit phage • Phage discovery effort pr
Slide 17: Pipeline
17 I Pipeline Pathogen Discovery Preclinical Clinical Plans / Indications Pseudomonas aeruginosa Staphylococcus aureus Undisclosed Partnered AP - PA02 Phage libraries to address market expansion and new indications AP - SA01 AP - SA02 Undisclosed Indication Bacteremia*, Respiratory Infections * pend
Slide 18: Phage Product Targeting Staphylococcus aureus
18 I Phage Product Targeting Staphylococcus aureus Existing drug product (AP - SA01) • Covers >95% of clinical isolates • 3 highly - related lytic phages of one family Human exposure obtained through EINDs • Compassionate use supported safety and efficacy, but did not probe optimal dose or regimen •
Slide 19: Strong Global IP Position Through Pending and Issued Patents
19 I Strong Global IP Position Through Pending and Issued Patents 12 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiries through 2038 Armata’s patents and applications cover: Therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof Compositi
Slide 20: Anticipated Topline Milestones 2019/2020
20 I Pseudomonas phage product candidate, AP - PA02 • File Clinical Trial Application (CTA) with relevant competent authorities in Europe • File US IND • Initiate first - in - human clinical study Staphylococcus phage product • Obtain nondilutive financing to initiate clinical study in S. aureus bac
Slide 21: Investment Highlights: A World-Leader in Phage Therapeutics
21 I Investment Highlights A World - Leader in Phage Therapeutics Two candidates positioned to enter clinical development Natural phage discovery and synthetic biology yield robust pipeline Merck partnership to develop proprietary synthetic phage to target an undisclosed infectious disease agent Pha
Slide 22: Armata Pharmaceuticals
‘» ARMATA PHARMACEUTICALS PURPOSEFUL @ PRECISE ¢ POWERFUL
Armata Pharmaceuticals — Ladenburg Thalmann 2019 Healthcare Conference on 6ix